ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VRX Bausch Health Cos

23.40
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Bausch Health Cos NYSE:VRX NYSE Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 23.40 0.00 01:00:00

TroyGould Advises Haitong International in its $190 Million Acquisition of Obagi Skincare Products Business

16/11/2017 6:00pm

PR Newswire (US)


Valeant Pharma (NYSE:VRX)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Valeant Pharma Charts.

LOS ANGELES, Nov. 16, 2017 /PRNewswire/ -- TroyGould advised Haitong International Zhonghua Finance Acquisition Fund I, L.P. (the "Fund") in its $190 million cash acquisition of the Obagi Medical Products business from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX).  The Obagi line of premium skincare products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage and are primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals.

Limited partners in the Fund included an affiliate of China Regenerative Medicine International Limited, a Hong Kong Stock Exchange company principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products.

"This transaction marked the buyer group's inaugural acquisition in the US space, which we were delighted to facilitate," TroyGould Partner, David Ficksman, commented.

Dale Short, the Administrative Chair of TroyGould's Corporate Group added, "The acquisition highlighted TroyGould's results oriented approach and deep bench of experience in cross-border transactions, mergers and acquisitions, licensing and distribution arrangements, transition services, the biotech space and intellectual property matters.  We rolled up our sleeves and worked alongside our client to deliver an excellent result."

The TroyGould team was led by Partner David Ficksman and Chinese-speaking attorneys Dietrick Miller and Calvin Cheng, each of whom have deep experience handling complex, cross-border transactions.  Other attorneys on the TroyGould team included Sharon Gold, who advised on intellectual property matters, Martin Goldblum, who advised on tax matters, and Tony Shin and Christian Hollweg, who provided transactional advice.

About TroyGould

TroyGould is an innovative, mid-sized firm that uses creative and cost-effective means to help its clients achieve their goals.  The firm's clients range from start-ups to middle-market and Fortune 500 companies in a variety of industries, including life sciences, entertainment, real estate, technology, financial services, manufacturing, media, consumer products, health care and natural resources.  For more information, visit TroyGould.com.

View original content:http://www.prnewswire.com/news-releases/troygould-advises-haitong-international-in-its-190-million-acquisition-of-obagi-skincare-products-business-300557910.html

SOURCE TroyGould

Copyright 2017 PR Newswire

1 Year Valeant Pharma Chart

1 Year Valeant Pharma Chart

1 Month Valeant Pharma Chart

1 Month Valeant Pharma Chart

Your Recent History

Delayed Upgrade Clock